http://www.unboundmedicine.com/medline/ebm/research/alemtuzumabUnbound MEDLINE is a service provided by Unbound Medicine, Inc. that includes data and services from the U.S. National Library of Medicine's MEDLINE® and PubMed® databases.en-usUnbound Medicine, Inc.http://www.unboundmedicine.com/medline/ebm/record/19920920/full_citation/The_evolving_role_of_alemtuzumab__Campath_1H__in_renal_transplantation_Pham PT, Lipshutz GS, Pham PT, et al. 
The evolving role of alemtuzumab (Campath-1H) in renal transplantation. [JOURNAL ARTICLE]
Drug Des Devel Ther 2009.:41-49.
Abstract | Full Citation | Find Related Articles http://www.unboundmedicine.com/medline/ebm/record/19920781/full_citation/A_Randomized_Trial_of_Alemtuzumab_Versus_Antithymocyte_Globulin_Induction_in_Renal_and_Pancreas_Transplantation_Farney AC, Doares W, Rogers J, et al. 
A Randomized Trial of Alemtuzumab Versus Antithymocyte Globulin Induction in Renal and Pancreas Transplantation. [JOURNAL ARTICLE]
Transplantation 2009 Sep 27; 88(6):810-819.
Abstract | Full Citation | Publisher Full Text | Find Related Articles http://www.unboundmedicine.com/medline/ebm/record/19920779/full_citation/Kidney_After_Nonrenal_Transplantation_The_Impact_of_Alemtuzumab_Induction_Shapiro R, Basu A, Tan HP, et al. 
Kidney After Nonrenal Transplantation-The Impact of Alemtuzumab Induction. [JOURNAL ARTICLE]
Transplantation 2009 Sep 27; 88(6):799-802.
Abstract | Full Citation | Publisher Full Text | Find Related Articles http://www.unboundmedicine.com/medline/ebm/record/19918163/full_citation/Aggressive_Posttransplant_Lymphoproliferative_Disease_in_a_Renal_Transplant_Patient_Treated_With_Alemtuzumab_Muzaffar M, Taj A, Ratnam S 
Aggressive Posttransplant Lymphoproliferative Disease in a Renal Transplant Patient Treated With Alemtuzumab. [JOURNAL ARTICLE]
Am J Ther 2009 Nov 14.
Abstract | Full Citationhttp://www.unboundmedicine.com/medline/ebm/record/19917859/full_citation/Epstein_Barr_Virus_Positive_Diffuse_Large_B_Cell_Lymphoma_During_Therapy_With_Alemtuzumab_for_T_Cell_Prolymphocytic_Leukemia_Sohani AR, Ferry JA, Chang PS, et al. 
Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma During Therapy With Alemtuzumab for T-Cell Prolymphocytic Leukemia. [JOURNAL ARTICLE]
J Clin Oncol 2009 Nov 16.
Full Citation | Publisher Full Text | Find Related Articles http://www.unboundmedicine.com/medline/ebm/record/19911856/full_citation/Current_and_emerging_treatments_for_chronic_lymphocytic_leukaemia_Robak T, Jamroziak K, Robak P 
Current and emerging treatments for chronic lymphocytic leukaemia. [Journal Article]
Drugs 2009; 69(17):2415-49.
Abstract | Full Citation | Find Related Articles http://www.unboundmedicine.com/medline/ebm/record/19899240/full_citation/Alemtuzumab_Bates D 
Alemtuzumab. [Comment, Editorial]
Int MS J 2009 Sep; 16(3):75-6.
Abstract | Full Citation | Publisher Full Text | Find Related Articles http://www.unboundmedicine.com/medline/ebm/record/19898186/full_citation/Intravitreal_alemtuzumab_penetrates_full_thickness_retina_in_rabbit_eyes_Ekdawi NS, Pulido JS, Itty S, et al. 
Intravitreal alemtuzumab penetrates full-thickness retina in rabbit eyes. [Journal Article]
Retina 2009 Nov-Dec; 29(10):1532-4.
Abstract | Full Citationhttp://www.unboundmedicine.com/medline/ebm/record/19896080/full_citation/A_novel_GVHD_prophylaxis_with_low_dose_alemtuzumab_in_allogeneic_sibling_or_unrelated_donor_hematopoetic_cell_transplantation:_the_feasibility_of_deescalation_Bertz H, Spyridonidis A, Wäsch R, et al. 
A novel GVHD-prophylaxis with low-dose alemtuzumab in allogeneic sibling or unrelated donor hematopoetic cell transplantation: the feasibility of deescalation. [Journal Article]
Biol Blood Marrow Transplant 2009 Dec; 15(12):1563-70.
Abstract | Full Citationhttp://www.unboundmedicine.com/medline/ebm/record/19895616/full_citation/Circulating_CD52_and_CD20_levels_at_end_of_treatment_predict_for_progression_and_survival_in_patients_with_chronic_lymphocytic_leukaemia_treated_with_fludarabine_cyclophosphamide_and_rituximab__FCR__Alatrash G, Albitar M, O'Brien S, et al. 
Circulating CD52 and CD20 levels at end of treatment predict for progression and survival in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab (FCR). [JOURNAL ARTICLE]
Br J Haematol 2009 Nov 6.
Abstract | Full Citation | Find Related Articles